Omeros ROE 2009-2018 | OMER

Current and historical return on equity (ROE) values for Omeros (OMER) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Omeros ROE for the three months ending December 31, 2018 was 0.00%.
Omeros ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-12-31 $-0.13B $-0.10B 185.40%
2018-09-30 $-0.12B $-0.09B 271.19%
2018-06-30 $-0.09B $-0.06B 445.57%
2018-03-31 $-0.07B $-0.03B 348.72%
2017-12-31 $-0.05B $-0.00B 218.56%
2017-09-30 $-0.06B $0.01B 170.99%
2017-06-30 $-0.06B $-0.06B 154.60%
2017-03-31 $-0.06B $-0.05B 157.96%
2016-12-31 $-0.07B $-0.04B 181.33%
2016-09-30 $-0.07B $-0.02B 195.68%
2016-06-30 $-0.07B $-0.05B 236.80%
2016-03-31 $-0.08B $-0.04B 458.82%
2015-12-31 $-0.08B $-0.03B 6080.00%
2015-09-30 $-0.08B $-0.01B 1400.00%
2015-06-30 $-0.08B $0.01B 750.00%
2015-03-31 $-0.08B $0.02B 515.25%
2014-12-31 $-0.07B $-0.04B 389.47%
2014-09-30 $-0.06B $-0.03B 431.37%
2014-06-30 $-0.05B $-0.01B 425.00%
2014-03-31 $-0.05B $0.01B 383.67%
2013-12-31 $-0.04B $-0.02B 228.57%
2013-09-30 $-0.05B $-0.02B 311.86%
2013-06-30 $-0.05B $-0.01B 500.00%
2013-03-31 $-0.04B $-0.02B 355.56%
2012-12-31 $-0.04B $-0.01B 371.43%
2012-09-30 $-0.04B $-0.00B 400.00%
2012-06-30 $-0.04B $-0.02B 388.89%
2012-03-31 $-0.03B $-0.01B 2480.00%
2011-12-31 $-0.03B $-0.01B -504.35%
2011-09-30 $-0.03B $0.00B -212.24%
2011-06-30 $-0.03B $0.01B -158.82%
2011-03-31 $-0.03B $0.02B -136.36%
2010-12-31 $-0.03B $0.02B -109.09%
2010-09-30 $-0.03B $0.02B -87.22%
2010-06-30 $-0.03B $0.03B -104.17%
2010-03-31 $-0.02B $0.04B -139.39%
2009-12-31 $-0.02B $0.04B -289.66%
2009-09-30 $-0.02B $-0.01B 428.57%
2009-06-30 $-0.02B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.868B $0.030B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $140.623B 27.80
Medtronic (MDT) Ireland $123.520B 18.06
Stryker (SYK) United States $73.875B 27.09
Boston Scientific (BSX) United States $52.874B 25.78
Baxter (BAX) United States $40.209B 25.72
Zimmer Biomet Holdings (ZBH) United States $26.486B 16.96
Smith & Nephew SNATS (SNN) United Kingdom $17.634B 0.00
Canopy Growth (CGC) Canada $15.407B 0.00
ResMed (RMD) United States $14.469B 27.44
Aurora Cannabis (ACB) Canada $9.687B 68.36
Bio-Rad Laboratories (BIO) United States $9.455B 53.94
Hill-Rom Holdings (HRC) United States $7.140B 22.08
Perrigo (PRGO) Ireland $6.601B 10.70
Insulet (PODD) United States $6.039B 2037.40
GW Pharmaceuticals (GWPH) United Kingdom $5.309B 0.00
ICU Medical (ICUI) United States $4.841B 30.14
Haemonetics (HAE) United States $4.496B 39.88
Hutchison China MediTech (HCM) China $3.961B 0.00
Agios Pharmaceuticals (AGIO) United States $3.830B 0.00
Neogen (NEOG) United States $3.332B 51.18
NuVasive (NUVA) United States $2.927B 25.53
Quidel (QDEL) United States $2.672B 24.11
Aphria (APHA) $2.518B 111.78
National Vision Holdings (EYE) United States $2.327B 45.77
HEXO (HEXO) $1.429B 0.00
Cardiovascular Systems (CSII) United States $1.402B 1006.25
Phibro Animal Health (PAHC) United States $1.308B 18.80
VAREX IMAGING (VREX) United States $1.299B 25.44
AtriCure (ATRC) United States $1.104B 0.00
Lantheus Holdings (LNTH) United States $0.968B 26.15
MacroGenics (MGNX) United States $0.967B 0.00
Cerus (CERS) United States $0.885B 0.00
PetIQ (PETQ) United States $0.872B 24.96
NanoString Technologies (NSTG) United States $0.753B 0.00
Meridian Bioscience (VIVO) United States $0.727B 21.67
OraSure Technologies (OSUR) United States $0.713B 31.24
Eagle Pharmaceuticals (EGRX) United States $0.705B 23.99
Evolus (EOLS) United States $0.701B 0.00
TG Therapeutics (TGTX) United States $0.650B 0.00
Surmodics (SRDX) United States $0.618B 89.94
LeMaitre Vascular (LMAT) United States $0.614B 29.21
Quanterix (QTRX) United States $0.551B 0.00
BioLife Solutions (BLFS) United States $0.397B 163.54
Vapotherm (VAPO) United States $0.371B 0.00
Rockwell Medical (RMTI) United States $0.363B 0.00
Insys Therapeutics (INSY) United States $0.358B 0.00
Utah Medical Products (UTMD) United States $0.312B 20.30
Owens & Minor (OMI) United States $0.284B 3.94
Bovie Medical (APYX) United States $0.264B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.257B 0.00
Cytosorbents (CTSO) United States $0.255B 0.00
Zynex (ZYXI) United States $0.143B 15.35
Fonar (FONR) United States $0.143B 7.64
Surface Oncology (SURF) United States $0.117B 0.00
Chimerix (CMRX) United States $0.102B 0.00
Female Health (VERU) United States $0.100B 0.00
Chembio Diagnostics (CEMI) United States $0.097B 0.00
InfuSystems Holdings (INFU) United States $0.090B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.088B 0.00
United-Guardian (UG) United States $0.087B 20.01
CAS Medical Systems (CASM) United States $0.071B 0.00
Trinity Biotech (TRIB) Ireland $0.071B 21.00
Neurotrope (NTRP) United States $0.061B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.056B 0.00
ImmuCell (ICCC) United States $0.038B 0.00
Valeritas Holdings (VLRX) United States $0.036B 0.00
Senestech (SNES) United States $0.028B 0.00
Myomo (MYO) United States $0.022B 0.00
Capricor Therapeutics (CAPR) United States $0.018B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
Akers Biosciences Inc (AKER) United States $0.014B 0.00
Cellectar Biosciences (CLRB) United States $0.012B 0.00
NeuroMetrix (NURO) United States $0.009B 15.57